Metabolomic profiling of urine-derived extracellular vesicles from rat model of drug-induced acute kidney injury

Saito, Masayoshi; Horie, Satoshi; Yasuhara, Hidenori; Kashimura, Akane; Sugiyama, Eiji; Saijo, Takeaki; Mizuno, Hajime; Kitajima, Hiroshi; Todoroki, Kenichiro

doi:10.1016/j.bbrc.2021.01.082

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in urinary extracellular vesicles have also been described in animal models of drug-induced nephrotoxicity (53), ischemia-reperfusion injury (54), AKI (55), and polyarteritis nodosa nephritis (56). Yet, species differences must be considered in application of data obtained from animal models.…”

Section: Extracellular Vesicles: Diagnostic Tools In Kidney Diseasementioning

confidence: 99%

Extracellular Vesicles as Theranostic Tools in Kidney Disease

Huang

Zhu

Lerman

et al. 2022

CJASN

View full text Add to dashboard Cite

Extracellular vesicles are important vectors for cell-cell communication and show potential value for diagnosis and treatment of kidney diseases. The pathologic diagnosis of kidney diseases relies on kidney biopsy, whereas collection of extracellular vesicles from urine or circulating blood may constitute a less invasive diagnostic tool. In particular, urinary extracellular vesicles released mainly from resident kidney cells might provide an alternative tool for detection of kidney injury. Because extracellular vesicles mirror many features of their parent cells, cargoes of several populations of urinary extracellular vesicle are promising biomarkers for disease processes like diabetic kidney disease, kidney transplant, and lupus nephritis. Contrarily, extracellular vesicles derived from reparative cells, such as mesenchymal stem cells, tubular epithelial progenitor cells, and human umbilical cord blood represent promising regenerative tools for treatment of kidney diseases. Furthermore, induced pluripotent stem cell-derived and engineered extracellular vesicles are being developed for specific applications for the kidney. Nevertheless, some assumptions regarding the specificity and immunogenicity of extracellular vesicles remain to be established. This review focuses on the utility of extracellular vesicles as therapeutic and diagnostic (theranostic) tools in kidney diseases and future directions for studies.

show abstract

Section: Extracellular Vesicles: Diagnostic Tools In Kidney Diseasementioning

confidence: 99%

Extracellular Vesicles as Theranostic Tools in Kidney Disease

Huang

Zhu

Lerman

et al. 2022

CJASN

View full text Add to dashboard Cite

show abstract

“…These proteins have a very low density and require a specific step (e.g., ultracentrifugation) for the isolation of the components of this fraction. Information on composition and proteomics obtained from EVs is useful for both basic and translational studies (C. L. Chen et al, 2012; Prikryl et al, 2021; Saito et al, 2021). Approximately 3000–6000 proteins have been identified in the normal urine proteome by combining LC‐MS/MS with the pretreatment of protein fractions (Aitekenov et al, 2021; Swensen et al, 2021).…”

Section: Targeted Quantification Of Proteins In Urine and Urinary Ext...mentioning

confidence: 99%

Targeted protein quantitation in human body fluids by mass spectrometry

Chen

Liao

Wang

et al. 2022

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Human body fluids (biofluids) contain various proteins, some of which reflect individuals' physiological conditions or predict diseases. Therefore, the analysis of biofluids can provide substantial information on novel biomarkers for clinical diagnosis and prognosis. In the past decades, mass spectrometry (MS)‐based technologies have been developed as proteomic strategies not only for the identification of protein biomarkers but also for biomarker verification/validation in body fluids for clinical applications. The main advantage of targeted MS‐based methodologies is the accurate and specific simultaneous quantitation of multiple biomarkers with high sensitivity. Here, we review MS‐based methodologies that are currently used for the targeted quantitation of protein components in human body fluids, especially in plasma, urine, cerebrospinal fluid, and saliva. In addition, the currently used MS‐based methodologies are summarized with a specific focus on applicable clinical sample types, MS configurations, and acquisition modes.

show abstract

“…Urine, the second most used diagnostic biofluid after blood, owing to its non-invasive sample access, availability in large quantity, and easy repeat measurements, contains a mixture of EVs derived from the urogenital tract, including kidneys, bladder, and prostate [5,6]. Over the last decade, urinary EV (uEV) has emerged as a promising diagnostic tool for various diseases, reflecting physiological and pathological conditions in the kidney, urothelial, and prostate tissues [7][8][9]. High-throughput proteomics technologies combined with standard analytical methods have identified numerous potential uEV biomarkers for prostate, bladder, and kidney cancers [10][11][12]; however, many newly discovered candidates have yet to undergo validation in extensive, multi-centered cohort studies, and the clinical transition is yet to be made.…”

Section: Introductionmentioning

confidence: 99%

Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis

Lee,

Kim,

Park

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Extracellular vesicles (EVs) contain a variety of biomolecules and provide information about the cells that produce them. EVs from cancer cells found in urine can be used as biomarkers to detect cancer, enabling early diagnosis and treatment. The potential of alpha-2-macroglobulin (A2M) and clusterin (CLU) as novel diagnostic urinary EV (uEV) biomarkers for bladder cancer (BC) was demonstrated previously. To validate the diagnostic value of these proteins in uEVs in a large BC cohort, urine handling conditions before uEV isolation should be optimized during sample transportation from medical centers. In this study, we analyzed the uEV protein quantity, EV particle number, and uEV-A2M/CLU after urine storage at 20°C and 4°C for 0–6 days, each. A2M and CLU levels in uEVs were relatively stable when stored at 4°C for a maximum of three days and at 20°C for up to 24 h, with minimal impact on analysis results. Interestingly, pre-processing to remove debris and cells by centrifugation and filtration of urine did not show any beneficial effects on the preservation of protein biomarkers of uEVs during storage. Here, the importance of optimizing shipping conditions to minimize the impact of pre-analytical handling on the uEVs protein biomarkers was emphasized. These findings provide insights for the development of clinical protocols that use uEVs for diagnostic purposes.

show abstract

Metabolomic profiling of urine-derived extracellular vesicles from rat model of drug-induced acute kidney injury

Cited by 6 publications

References 17 publications

Extracellular Vesicles as Theranostic Tools in Kidney Disease

Extracellular Vesicles as Theranostic Tools in Kidney Disease

Targeted protein quantitation in human body fluids by mass spectrometry

Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis

Contact Info

Product

Resources

About